Trove
Sign In Sign Up

iRhythm Technologies

Organization
Mentions
6
Relationships
1
Events
0
Documents
3
Also known as:
iRhythm Technologies, Inc.
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.
1 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
person NLV-II
Investment portfolio
5
1
View
No events found for this entity.

HOUSE_OVERSIGHT_024050.jpg

This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.

Investment memorandum / fund report
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024023.jpg

This document is a page from a corporate prospectus or due diligence report (marked Confidential, House Oversight) detailing the professional biographies of three Managing Directors at New Leaf (presumably New Leaf Venture Partners): Jeani Delagardelle, Ron Hunt, and Vijay Lathi. All three were previously associated with Sprout Group. The document lists their educational backgrounds and extensive board memberships across various pharmaceutical and medical technology companies.

Corporate prospectus / biography page / due diligence report
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024100.jpg

This document is a confidential financial appendix (Appendix 1) labeled 'Listing of Investments by Fund' for New Leaf Ventures II, L.P., dated March 31, 2014. It details the financial performance of numerous healthcare, therapeutic, and diagnostic companies in the fund's portfolio, split into realized/partially realized and unrealized investments. The document bears a House Oversight Committee stamp and a confidential control number, indicating it is part of a congressional investigation.

Financial report / investment schedule
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$0.00
0 transactions
Net Flow
$0.00
0 total transactions
No financial transactions found for this entity. Entity linking may need to be improved.
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search